Somerset Medical Center has long been dedicated to providing accessible, evidence-based health information to the public. This commitment has historically covered a wide range of topics, from preventive care to treatment options. As medical knowledge evolves, the same principles of clarity and accuracy must be applied to emerging areas of concern. One such area involves the relationship between pharmaceutical exposure and specific health outcomes. In particular, the transition from general health education to occupational exposure concern requires careful attention. Workers in healthcare and pharmaceutical manufacturing may encounter substances at higher concentrations or frequencies than the general population, necessitating focused risk communication. This shift demands that we apply the same rigorous standards of information dissemination to workplace settings. By leveraging established trust in health science communication, we can effectively address questions about exposure risks without overstepping into mechanistic claims. The goal remains to inform, not to diagnose, while recognizing that occupational contexts introduce distinct variables that warrant specialized attention. This transition respects the legacy of general health education while adapting to contemporary needs.
Building on our foundation of general health education, we now turn to a specific and important topic: the association between Fosamax (alendronate) and osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ is a recognized adverse effect associated with bisphosphonate use, including Fosamax. It is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation involves areas of exposed bone in the maxillofacial region that persist for more than eight weeks, often accompanied by pain, swelling, and infection. Diagnosis is typically based on clinical examination and imaging, with histopathology confirming necrotic bone. The condition can lead to significant morbidity, including difficulty eating, speaking, and maintaining oral hygiene.
Fosamax pharmacology involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. This mechanism, while beneficial for increasing bone mass and reducing fracture risk in osteoporosis, can impair the normal remodeling and repair processes in the jawbone. The jawbone has unique structural and metabolic characteristics that may make it particularly susceptible to bisphosphonate-related complications. A multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The reduced bone turnover can lead to microdamage accumulation and impaired healing after dental procedures, creating an environment conducive to ONJ development. The time to onset of ONJ symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). A cohort study among cancer-free female patients aged 40-89 with, or at risk for, osteoporosis in the United Kingdom Clinical Practice Research Datalink (CPRD Aurum) found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation (https://pubmed.ncbi.nlm.nih.gov/39400702/). This study provides important epidemiological evidence quantifying the risk of ONJ in osteoporosis patients treated with antiresorptives like Fosamax.
From a causation perspective, the relationship between Fosamax and ONJ is supported by mechanistic plausibility (bisphosphonate-induced suppression of bone turnover in the jaw), temporal association (onset can occur from days to months after starting the drug, and risk increases with longer exposure), and epidemiological evidence (increased risk with longer treatment duration). However, ONJ is a rare event, and the absolute risk in osteoporosis patients is low. The condition is not exclusive to bisphosphonate use and can occur spontaneously or in association with other risk factors. For affected patients, clinical interpretation should consider the individual's risk profile, including duration of Fosamax use, presence of other risk factors (e.g., dental procedures, cancer, corticosteroid use), and the severity of ONJ symptoms. Discontinuation of Fosamax may lead to symptom relief in most patients, and for those requiring invasive dental procedures, temporary discontinuation may reduce ONJ risk. The optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, Fosamax is associated with an increased risk of ONJ, particularly with longer duration of use and in the presence of other risk factors. The evidence supports a causal link through mechanistic pathways involving suppressed bone turnover in the jaw, with epidemiological data showing a dose-response relationship. However, the absolute risk remains low, and clinical management should balance the benefits of fracture prevention against the rare risk of ONJ.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.
Fosamax (alendronate) is a bisphosphonate medication used to treat and prevent osteoporosis in postmenopausal women, increase bone mass in men with osteoporosis, treat glucocorticoid-induced osteoporosis, and treat Paget's disease of bone. It works by inhibiting osteoclast-mediated bone resorption, thereby reducing bone turnover and increasing bone density (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, often associated with tooth extraction or local infection. It is a recognized adverse effect of bisphosphonate use, including Fosamax. The risk increases with longer duration of use and presence of other risk factors such as invasive dental procedures, cancer, corticosteroid use, and poor oral hygiene (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
ONJ is rare in osteoporosis patients taking Fosamax. A cohort study found that the absolute risk is approximately 0.05% after 5 years of treatment. However, the risk increases with longer exposure: threefold higher after 2-3 years and eightfold after 10 years compared to past use (https://pubmed.ncbi.nlm.nih.gov/39400702/).
If you require invasive dental procedures, your healthcare provider may recommend temporarily discontinuing Fosamax to reduce the risk of ONJ. It is important to discuss your medication history with your dentist and doctor to plan appropriate management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
No. Submission requests an initial records screening only and does not create an medical context-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.